News | June 09, 2024
Gavi outlines plans to support access to new vaccines
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
India is working towards augmenting health infrastructure and have initiated multiple schemes to strengthen health systems and improve health service delivery
The vaccine was 85 percent effective in preventing severe disease across all regions.
Subscribe To Our Newsletter & Stay Updated
